Wall Street brokerages assume that Profound Medical Corp. (NASDAQ:PROF – Get Score) will write-up income of $2.00 million for the existing quarter, Zacks Financial commitment Study stories. Two analysts have created estimates for Profound Medical’s earnings. Profound Medical posted revenue of $2.63 million throughout the same quarter previous calendar year, which would advise a adverse yr more than yr growth fee of 24%. The organization is scheduled to report its up coming quarterly earnings final results on Monday, January 1st.
According to Zacks, analysts expect that Profound Medical will report total year gross sales of $10.22 million for the present-day yr, with estimates ranging from $8.00 million to $12.00 million. For the up coming financial calendar year, analysts count on that the enterprise will report gross sales of $27.89 million, with estimates ranging from $22.00 million to $35.00 million. Zacks Investment decision Research’s product sales averages are an average centered on a study of analysts that follow Profound Medical.
Profound Medical (NASDAQ:PROF – Get Ranking) very last announced its quarterly earnings effects on Thursday, March 3rd. The enterprise claimed ($.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($.35) by ($.14). The organization had income of $1.00 million for the quarter, compared to analyst estimates of $2.80 million. Profound Medical experienced a detrimental return on equity of 37.74% and a destructive web margin of 417.41%. For the duration of the exact same quarter past yr, the organization posted ($.38) EPS.
Various analysts have just lately weighed in on the company. Cowen slash their cost objective on Profound Medical from $28.00 to $14.00 and established an “outperform” score for the business in a report on Monday, March 7th. Zacks Expense Study upgraded Profound Medical from a “sell” rating to a “hold” ranking in a report on Friday, May perhaps 13th. Raymond James established a $22.00 rate objective on Profound Medical and gave the enterprise an “outperform” rating in a report on Tuesday, May 10th. Finally, Alliance Worldwide Companions lower their value goal on Profound Medical from $16.25 to $12.00 and established a “buy” score for the business in a report on Tuesday, May perhaps 10th.
Shares of Profound Medical stock opened at $7.78 on Thursday. The business has a sector cap of $161.67 million, a selling price-to-earnings ratio of -5.08 and a beta of 1.11. The business enterprise has a fifty working day easy transferring normal of $8.12 and a 200-day simple going normal of $9.63. Profound Medical has a fifty-two 7 days lower of $6.09 and a fifty-two 7 days substantial of $19.32.
Numerous institutional investors have recently created improvements to their positions in the enterprise. Timelo Expenditure Management Inc. obtained a new position in Profound Medical all through the fourth quarter valued at $10,056,000. Letko Brosseau & Associates Inc. raised its place in Profound Medical by 58.% all through the initial quarter. Letko Brosseau & Associates Inc. now owns 1,299,125 shares of the company’s inventory valued at $11,701,000 soon after obtaining an further 476,875 shares through the time period. Deerfield Administration Company L.P. Sequence C raised its situation in Profound Medical by 32.1% in the course of the fourth quarter. Deerfield Administration Business L.P. Collection C now owns 1,713,797 shares of the company’s stock valued at $19,246,000 right after obtaining an supplemental 416,000 shares through the interval. Gagnon Securities LLC raised its posture in Profound Medical by 22.9% in the course of the first quarter. Gagnon Securities LLC now owns 1,324,335 shares of the company’s inventory valued at $11,919,000 just after acquiring an supplemental 246,978 shares through the interval. Ultimately, FIL Ltd elevated its place in Profound Medical by 14.3% during the third quarter. FIL Ltd now owns 1,000,375 shares of the company’s inventory valued at $14,604,000 soon after obtaining an additional 125,030 shares during the period. 60.23% of the stock is presently owned by institutional investors.
About Profound Medical (Get Score)
Profound Medical Corp., jointly with its subsidiaries, operates as a industrial-stage medical system enterprise that develops magnetic resonance guided ablation strategies for treatment of prostate disease, uterine fibroids, and palliative agony treatment in Canada, Germany, the United States, and Finland.
Featured Article content
Get a absolutely free duplicate of the Zacks investigation report on Profound Medical (PROF)
For far more data about investigate choices from Zacks Expense Investigate, pay a visit to Zacks.com
Acquire News & Scores for Profound Medical Day-to-day – Enter your e-mail address under to receive a concise each day summary of the latest information and analysts’ ratings for Profound Medical and related providers with MarketBeat.com’s Absolutely free each day electronic mail newsletter.
